Sign In
Buy AMPH
$19.94
-0.440 (-2.16%)
At Close: Jul 31, 2026
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 29'th Apr 2026
Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Wednesday, 29'th Apr 2026
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
10:42am, Wednesday, 29'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
06:00am, Monday, 06'th Apr 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulato
SG Americas Securities LLC Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH
05:01am, Saturday, 04'th Apr 2026
SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exc
Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?
04:09am, Wednesday, 01'st Apr 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving averag
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:52am, Monday, 16'th Mar 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here
12:18am, Monday, 16'th Mar 2026
Amphastar Pharmaceuticals (AMPH) is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low – Here’s Why
01:33am, Sunday, 08'th Mar 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $19.54 and last traded at $20.44, with a
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label
08:25am, Saturday, 28'th Feb 2026
Amphastar Pharmaceuticals remains a 'Hold' as growth and margin headwinds persist amid its transition from generics to a proprietary pipeline. AMPH's legacy generics are declining, branded products fa
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade
02:48am, Saturday, 28'th Feb 2026
Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) gapped down prior to trading on Friday after Wells Fargo and Company lowered their price target on the stock from $34.00 to $
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics
09:30pm, Thursday, 26'th Feb 2026
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall St
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
09:27pm, Thursday, 26'th Feb 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
06:31pm, Thursday, 26'th Feb 2026
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.92 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
04:05pm, Thursday, 26'th Feb 2026
Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or
